
Anti-Inflammatory and Anti-Diabetic Therapy for Metabolic SyndromeAward last edited on: 2/3/2021
Sponsored Program
SBIRAwarding Agency
NIH : NIDDKTotal Award Amount
$300,000Award Phase
1Solicitation Topic Code
847Principal Investigator
Ridong ChenCompany Information
APT Therapeutics Inc (AKA: Advanced Protein Technologies Inc.)
4041 Forest Park Avenue
Saint Louis, MO 63108
Saint Louis, MO 63108
(314) 800-4742 |
info@apt-therapeutics.com |
www.apt-therapeutics.com |
Location: Single
Congr. District: 01
County: St. Louis city
Congr. District: 01
County: St. Louis city
Phase I
Contract Number: 1R43DK126493-01A1Start Date: 9/15/2020 Completed: 8/31/2021
Phase I year
2020Phase I Amount
$300,000Public Health Relevance Statement:
Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong Narrative: The proposed approach will decrease the risk for cardiovascular disease by treating the underlying metabolic disease and type 2 diabetes with weekly doses of a novel immunomodulator and insulin stimulator.
Project Terms:
abdominal fat; Adipose tissue; Affect; Affinity; Aldesleukin; Animal Model; Animals; Anti-Inflammatory Agents; Antibodies; Antidiabetic Drugs; Antihypertensive Agents; Atherosclerosis; attenuation; Binding; Binding Sites; Blood; Blood Glucose; blood glucose regulation; Blood Pressure; Blood Vessels; Body Weight; Brown Fat; Cancer Model; Carbohydrates; Cardiovascular Diseases; cardiovascular disorder risk; Cardiovascular system; CD8-Positive T-Lymphocytes; Cells; Central obesity; Chimeric Proteins; Complications of Diabetes Mellitus; cost; cytokine; Data; design; Development; Diabetes Mellitus; diabetic; Diet; Dilated Cardiomyopathy; Dose; Dyslipidemias; effector T cell; eosinophil; Eragrostis; Escherichia coli; Event; Family suidae; Fatty acid glycerol esters; FDA approved; FOXP3 gene; Fructose; Generations; glucagon-like peptide 1; glucose tolerance; Goals; Half-Life; Heart failure; High Fat Diet; Human; Hyperglycemia; Hyperinsulinism; Hypertension; IL2 gene; IL2RA gene; IL2RB gene; IL2RG gene; Immune; immunogenic; Immunomodulators; improved; In Vitro; Individual; Inflammation; Injection Site Reaction; Injections; innovation; Innovative Therapy; Insulin; Insulin Resistance; insulin sensitivity; insulin sensitizing drugs; Insulin-Dependent Diabetes Mellitus; Interferons; Interleukin-2; Investigational New Drug Application; Ischemic Stroke; Kidney; Leptin; Lipids; macrophage; Mammalian Cell; melanoma; Memory; Metabolic Diseases; Metabolic syndrome; Modeling; molecular size; Monkeys; Morbidity - disease rate; mortality; Mus; Mutation; Myocardial Infarction; Myocarditis; Natural Killer Cells; Non-Insulin-Dependent Diabetes Mellitus; Nonlytic; Normal tissue morphology; novel; novel strategies; Obese Mice; Obesity; Omentum; Pathogenicity; Pathologic; Pathway interactions; Patients; Pharmaceutical Preparations; Phase; Phenotype; Plasma; Play; Prediabetes syndrome; prevent; Prevention strategy; Principal Investigator; programs; protein E; Rattus; Reaction; receptor; Recombinants; Regulation; Regulatory T-Lymphocyte; Renal carcinoma; restoration; Risk Factors; Role; Safety; Serum Albumin; side effect; Site; Small Business Innovation Research Grant; standard of care; success; Syndrome; Th1 Cells; Therapeutic; Toxic effect; Triglycerides; Variant; Ventricular Remodeling; Visceral; Work
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00